Claude can now break down papers like an MIT researcher. Here are 10 insane Claude prompts that turn dense research papers into simple summaries, diagrams, limitations, experiments, and future research ideas in minutes (Save this)

Completely agree. Tolerability is more than adverse events. If reduced toxicity allows patients to stay on treatment longer without compromising target inhibition, it may become part of the efficacy pathway itself. Grateful to @HannahRAbrams for highlighting this concept and to @NagashreeSeeth1 for her mentorship on the work behind these observations.

Excited to see this work presented at #ASCO26. Patients with pre-existing autoimmune disease remain underrepresented in immunotherapy trials, and real-world data are critical to informing treatment decisions. Looking forward to seeing the results and discussion. @NehemiasGuevar5 @dominicandoc2 @oncodaily

Congrats to @NehemiasGuevar5 & team #ASCO26 Key takeaways for oncologists: 🔹 Autoimmune disease ≠ automatic exclusion from ICIs 🤔 Requires careful toxicity monitoring & patient selection 🤝 Strong oncology rheumatology collaboration is critical 🔹 Shared decision-making remains essential Important real-world data for everyday practice 💉🫁 #Immunotherapy @ASCOTECAG @hemeoncfellow @HemOncFellows @ASCO

Thank you @NarjustFlorezMD for building such a supportive community for trainees and early-career oncologists. It’s a great reminder of how much mentorship and community can shape our careers. @NehemiasGuevar5 #ASCO26

What environmental factors may contribute to lung cancer risk beyond smoking? Looking forward to presenting our #ASCO26 poster on ambient carbon tetrachloride exposure and lung cancer incidence in the U.S. Abstract: asco.org/abstracts-presentat… @NagashreeSeeth1 @NorthwellHealth

As oncology becomes increasingly complex, patient education is more important than ever. I'm grateful for the opportunity to work with @cancerGRACE on a patient education series focused on #ThyroidCancer, covering 🧬 Targeted therapies 🩺 Treatment pathways 📈 Management of recurrent thyroid cancer Video 30-32 youtube.com/playlist?list=PL… Translating rapidly evolving science into practical information for patients and caregivers remains an essential part of delivering high-quality cancer care. If you're in Chicago for #ASCO26, join us at the GRACE reception: 📍 Beatrix North 📅 May 29 🕖 7 PM #ThyroidCancer #PatientEducation #ASCO26 @NagashreeSeeth1 @JackWestMD @AmyBickleman @NehemiasGuevar5 @oncodaily @EliLillyandCo @ASCOTECAG

Now focusing on the rapid oral abstract head and neck cancers (Monday 6/1 at 4:30 PM CT)- a fascinating line up featuring novel therapeutics and strategies-hinting towards a brighter future

I used a team of ~30 AI agents to analyze 57,603 ASCO Abstracts between 2016-2025. Here are my top 6 learnings on the past decade of oncology open.substack.com/pub/liangc…

Excited to share our new publication with @NarjustFlorezMD @MImbimbo1 @COlazagasti on lung cancer diagnosed during pregnancy — a rare and highly complex clinical scenario requiring multidisciplinary care. frontiersin.org/journals/onc…

Conference season is upon us with poster sessions, #oralabstracts, and #grandrounds on the horizon! To help prepare, we wrote this #ASCOconnection article: 🔗 The High-Stakes Talk 🗣️ @jennifermarksmd @ASCO In the piece, we share practical strategies to: 🔹 Lead with the core message 🔹 Make the “so what” clear 🔹 And more Because strong science should be easy to understand, discuss, remember, and carry forward. 🙋🏾‍♂️What is the best presentation advice you have received or the one lesson you wish you had learned earlier? connection.asco.org/do/high-… #Oncology #MedEd #ASCOtips #PresentationTips #PosterPresentation #ResearchTalks @hemeoncfellow @HemOncFellows @SNMA @LmsaNational @ASCOTECAG @OncoAlert @oncodaily

#TumorBoardTuesday 🫁 Early-stage #NSCLC is no longer just surgery ➕ chemo: Molecular testing now shapes curative-intent Tx decisions 🧬 📢Join us Tuesday, 05-05-26 at 8PM ET as @NarjustFlorezMD & @NehemiasGuevar5 🗣️EGFR Early #NSCLC RT and bring others into the discussion‼️

Join us tomorrow at 8 PM ET for a deep dive into early-stage #NSCLC and #NeoADAURA @TumorBoardTues @NarjustFlorezMD @Florez_Lab @OncBrothers @COlazagasti @dominicandoc2 @oncodaily @Arthur_Aung @guicorreiamd @IMG_Oncologists @Shuai_WangOnc @HyeinJeon_MD @TejaVorugantiMD @OncLive

Honored to contribute to the discussion on thyroid cancer in 2026. Thank you to @oncodaily @NagashreeSeeth1 @DrMLChua @amanda_psyrri for organizing the summit.

Great catching up with @JackieAredoMD and soon-to-be faculty @TLCconference. #TexasLung

Amazing panel discussion on long-term immunotherapy outcomes in NSCLC, dual checkpoint blockade, and how we still need to refine patient selection. Grateful to learn from this group @benlevylungdoc @lungoncdoc @RachelSanbornMD @DasMillie11 #TexasLung